Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Endometrial Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; R ecurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma Interventions: Drug: Copanlisib; Drug: Niraparib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Endometrial Cancer | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Research | Serous Carcinoma